This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides

This study has been completed.
Information provided by (Responsible Party):
Yaupon Therapeutics Identifier:
First received: September 24, 2007
Last updated: August 7, 2012
Last verified: August 2012
To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or AP ointment who did not achieve a complete response.

Condition Intervention Phase
Mycosis Fungoides Drug: 0.04% Mechlorethamine gel Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response

Resource links provided by NLM:

Further study details as provided by Yaupon Therapeutics:

Primary Outcome Measures:
  • Evaluate the efficacy of topical application of NM 0.04% in a propylene glycol ointment (PG) in patients with stage I or IIA MF [ Time Frame: 7 months ]

Secondary Outcome Measures:
  • Evaluate the tolerability and safety of topical application of NM 0.04% ointment formulations in patients with stage I or IIA MF [ Time Frame: 7 months ]

Enrollment: 100
Study Start Date: July 2007
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Open label 0.04% Mechlorethamine gel
Drug: 0.04% Mechlorethamine gel
Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
Other Name: Nitrogen Mustard 0.04%

Detailed Description:
This is a multi-center, open-label study of patients with previously treated stage I (IA and IB) or IIA MF who have not received a complete response after completing 12 months of treatment in clinical trial (2005NMMF-201-US)to either 0.02% MCH PG or 0.02% MCH in Aquaphor (AP) ointment formulations.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have completed the treatment phase of the Yaupon Therapeutics-sponsored Phase II Pivotal study of MCH 0.02% in either the PG or AP formulation and have not achieved a complete response.

Exclusion Criteria:

  • Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00535470

United States, California
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Illinois
Northwestern University-Dept. of Dermatology
Chicago, Illinois, United States, 61611
United States, New York
Columbia University, Dept of Dermatology
New York, New York, United States, 10016
NYU Medical Center Dept. of Dermatology
New York, New York, United States, 10016
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Oklahoma
Oklahoma University
Tulsa, Oklahoma, United States, 74104
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111-2497
United States, Texas
University of Texas, Southwestern Medical Center
Dallas, Texas, United States, 75390
The University of Texas, M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Utah Clinical Trials, LLC
Salt Lake City, Utah, United States, 84107
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53791
Sponsors and Collaborators
Yaupon Therapeutics
Principal Investigator: Stuart Lessin, M.D. Fox Chase Cancer Center
  More Information

Responsible Party: Yaupon Therapeutics Identifier: NCT00535470     History of Changes
Other Study ID Numbers: 2007NMMF-202-US
Study First Received: September 24, 2007
Last Updated: August 7, 2012

Additional relevant MeSH terms:
Mycosis Fungoides
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Nitrogen Mustard Compounds
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Antineoplastic Agents processed this record on August 18, 2017